# TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT02083783** · PHASE3 · COMPLETED · sponsor: **Tris Pharma, Inc.** · enrollment: 108 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** TRI102
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02083783
- **Lead sponsor:** Tris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083783, "TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02083783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*